ADC Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

ADC Therapeutics Sarl (ADCT) is a pharmaceutical company that develops a pipeline of proprietary antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company is involved in combining monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells. ADCT conducts research on next-generation cancer biologic therapies. It targets a wide range of cancers such as breast lung, prostate, renal and blood cancer. The company has exclusive technology license partnership with Spirogen for the development of PBD-based Antibody-Drug-Conjugates. It also has corporate partnerships with MedImmune, Cancer Research Technology and Genmab. ADCT is headquartered in Lausanne, Switzerland.

ADC Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
Private Equity 14
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
Partnerships 15
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
Licensing Agreements 20
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
Synaffix Enters into Licensing Agreement with ADC Therapeutics 23
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 26
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 27
Equity Offering 28
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 28
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 29
ADC Therapeutics SA - Key Competitors 30
ADC Therapeutics SA - Key Employees 31
ADC Therapeutics SA - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Product Approvals 33
Jun 09, 2017: ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma 33
Clinical Trials 34
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data for ADCT-402 at American Society of Hematology 2017 Annual Meeting 34
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data on ADCT-301 at the American Society of Hematology 2017 Annual Meeting 35
Jun 16, 2017: ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma 36
Jun 16, 2017: ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List Of Tables

List of Tables
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
Synaffix Enters into Licensing Agreement with ADC Therapeutics 23
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 26
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 27
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 28
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 29
ADC Therapeutics SA, Key Competitors 30
ADC Therapeutics SA, Key Employees 31
ADC Therapeutics SA, Other Locations 32

List Of Figures

List of Figures
IBC Solar AG, Power, Deals By Year, 2012 to YTD 2018 22
IBC Solar AG, Power, Deals by Type, 2012 to YTD 2018 27